source
- Chinese partnerships are becoming the pharma industry's new tax inversion strategyThe article notes that a decade after the wave of U.S. tax inversions, the pharmaceutical sector is now seeing a similar pattern with deals involving Chinese entities. Analysts argue that these tra…
- Ipsen to acquire blood-cancer specialist Kartos Therapeutics for $450 million upfrontIpsen announced it will purchase Kartos Therapeutics, a company focused on blood cancers. The transaction includes a $450 million cash payment at closing, with the possibility of up to $1.75 billi…